Estela Prada Varela
Investigador post-doc
Research group
Research line:
Treatment of Pediatric Rabdomiosarcoma
The researcher has a degree in Pharmacy since 2014 from the University of Santiago de Compostela.
In 2015, she obtained a master's degree in Translational Biomedical Research from the Vall d'Hebron Research Institute - Universitat Autònoma de Barcelona.
In 2016 she joined as a predoctoral researcher in the Developmental Tumors laboratory of the Sant Joan de Déu Hospital of Dr. Jaume Mora for the development of new targets and pharmacological opportunities in the treatment of pediatric rhabdomyosarcoma.
In November 2021 she obtained her PhD from the University of Barcelona, with her doctoral thesis "Target therapy in Rhabdomyosarcoma: Discovering new targets and opportunities", supervised by Dr. Jaume Mora (SJD) and Dr. Inmaculada Hernandez (IMIM ).
She currently works as a postdoctoral researcher in the Sarcomas and Histiocytosis group, included in the IRSJD Pediatric Cancer program.
Professional network profiles
Last Publications
- Figuerola-Bou E, Rios-Astorch C, Blanco E, Sanchez-Jimenez M, Táboas-Outón P, Fernandez-Isern G, Gomez-Gonzalez S, Muñoz-Aznar O, Castellano-Escuder P, Pérez-Jaume S, Garcia-López M, Prada-Varela E, Mateo-Lozano S, Riggi N, Avgustinova A, Lavarino C, Di Croce L, Sánchez-Molina S and Mora J KDM6 Demethylases Contribute to EWSR1::FLI1-Driven Oncogenic Reprogramming in Ewing Sarcoma. CANCER RESEARCH . 85(22): 4485-4503.
- Prada-Varela E, Táboas-Outón P, Andrades E, Gomez-Gonzalez S, Mateo-Lozano S, Cebrià A, Berenguer-Molins P, Perera-Bel J, Arcon JP, Saen-Oon S, Díaz L, Gay M, Folch-I-Casanovas I, Odena A, Vilaseca M, Rovira Q, García-Gerique L, Rodriguez E, Rovira-Zurriaga C, Rodrigues G, Carcaboso AM, Avgustinova A, Hernandez-Muñoz MI and Mora J PRKG1 hinders myogenic differentiation and predicts response to AKT inhibitor ipatasertib in Rhabdomyosarcoma. NATURE COMMUNICATIONS . 16(1): 9816-9816.
- Hernandez-Muñoz MI, Cuervas I, Prada-Varela E, Pulecio J, Gimeno R, Andrades E, Gomez-Gonzalez S, Berenguer-Molins P, Acedo-Terrades A, Perera-Bel J, Bódalo-Torruella M, Nonell L, Pérez E, Grases D, Mata C, Yélamos J, Richaud-Patin Y, Vidal E, Cuartero Y, Le Dily F, Suñol M, Manzanares-Quintela A, Raya A and Mora J EWS::FLI1 expression in human embryonic mesenchymal stem cells leads to transcriptional reprograming, defective DNA damage repair and Ewing sarcoma NATURE COMMUNICATIONS . 16(1): 9427-9427.
Projects
- Project name:
- Caracterización y relevancia del entorno epigenético en el desarrollo del sarcoma de Ewing
- Leader
- Jaume Mora Graupera
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI16/00245
- Starting - finishing date:
- 2017 - 2020
- Project name:
- Fundación Leo Messi_Convenio Rabdomiosarcoma
- Leader
- Jaume Mora Graupera
- Funding entities:
- Fundación Privada Leo Messi
- Code
- PFNR0068
- Starting - finishing date:
- 2016 - 2019
- Project name:
- Rabdomiosarcoma
- Leader
- Jaume Mora Graupera
- Funding entities:
- Clientes Diversos
- Code
- PFNR0069
- Starting - finishing date:
- 2015 - 3000
News
-
Researchers Find the Cell of Origin of Ewing Sarcoma
Researchers suspect that the genetic alteration that triggers the mechanisms that generate this type of cancer occurs during embryonic development
-
Dr. Jaume Mora receives the IV FERO Dr. Baselga Grant to promote new therapies against pediatric cancer
The scientific director of the Pediatric Cancer Center Barcelona receives a grant of €300,000 for a three-year project aimed at developing more effective and less toxic treatments for childhood cancer.
